• Wortmannin PI3K Inhibitor: Advanced Workflows for Cancer Res

  2026-06-15

  Wortmannin, a gold-standard PI3K inhibitor from APExBIO, empowers researchers to probe PI3K/Akt/mTOR signaling, apoptosis, and ferroptosis resistance in cancer with unprecedented selectivity. This article translates the latest reference findings and protocol refinements into actionable workflows, troubleshooting strategies, and comparative insights for high-impact translational studies.

• Strategic Use of BPN-19186 for Liver-Bone Axis and sEH-Nrf2

  2026-06-15

  (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) enables advanced investigation of hepatic sEH–Nrf2 signaling in bone metabolism. This article uniquely focuses on protocol design, technical pitfalls, and translational implications for osteoporosis research.

• Dual-Action p38α MAPK Inhibitors Accelerate Dephosphorylatio

  2026-06-14

  The referenced study reveals that certain p38α MAPK inhibitors not only block kinase activity but also promote dephosphorylation by the WIP1 phosphatase, introducing a dual-action mechanism. These findings offer critical insights for designing more selective and potent kinase inhibitors, with implications for inflammation and disease research.

• EdU Flow Cytometry Assay Kits (Cy5): Precision S-Phase Detec

  2026-06-13

  Unlock high-sensitivity, multiplexable cell proliferation analysis with EdU Flow Cytometry Assay Kits (Cy5). This platform delivers robust S-phase DNA synthesis measurement—outperforming legacy BrdU methods—while supporting advanced workflows in cancer research and translational immunology.

• QX77: Molecular Chaperone Activator for Autophagy Research

  2026-06-12

  QX77 sets itself apart as a robust molecular chaperone activator, enabling precise control of chaperone-mediated autophagy and stem cell differentiation. Its unique modulation of lysosomal receptor pathways empowers high-fidelity modeling of autophagy, making it indispensable for translational cell biology and mechanistic pathway dissection.

• Scenario-Driven Solutions with Oligo (dT) 25 Beads (SKU K130

  2026-06-12

  This article delivers a scenario-driven, evidence-backed exploration of laboratory challenges in eukaryotic mRNA isolation, highlighting how Oligo (dT) 25 Beads (SKU K1306) address pain points with reproducibility and workflow efficiency. We provide practical guidance grounded in peer-reviewed data and validated protocols for biomedical researchers and technicians.

• ICG001: Wnt/β-Catenin Pathway Inhibitor in Translational Res

  2026-06-11

  ICG001 offers researchers a precise tool for dissecting Wnt/β-catenin signaling in cancer, fibrosis, and regenerative medicine. Its selective inhibition of CBP/β-catenin interactions enables high-fidelity pathway modulation and reduces off-target effects, providing clear advantages in both in vitro and in vivo models.

• 2,7-Dichlorodihydrofluorescein Diacetate for ROS Detection W

  2026-06-11

  2,7-Dichlorodihydrofluorescein diacetate (DCFH-DA) enables sensitive, quantitative assessment of intracellular ROS in live-cell systems, supporting diverse experimental platforms from fluorescence microscopy to high-throughput plate assays. Leveraging the latest mechanistic insights and troubleshooting strategies, researchers can optimize oxidative stress detection and translate findings across disease models.

• Phenytoin and AEDs Inhibit Human Serum Paraoxonase-1 Activit

  2026-06-10

  This study systematically quantifies how phenytoin and other antiepileptic drugs inhibit human serum paraoxonase-1 (hPON1) activity in vitro. The findings provide mechanistic insight into enzyme-drug interactions relevant for neurological disease models and highlight implications for oxidative stress and atherosclerotic risk in epilepsy therapy.

• RBMS1 Loss Sensitizes TNBC to PD-L1 Checkpoint Blockade

  2026-06-10

  The reference study identifies RBMS1 as a critical regulator of PD-L1 stability in triple-negative breast cancer (TNBC), showing that its depletion enhances anti-tumor immunity. These findings reveal a new post-transcriptional control point for immunotherapy and suggest combinatorial strategies to overcome immune-cold tumor resistance.

• Virus-Mimicking Nanoparticles for Targeted Extrahepatic mRNA

  2026-06-09

  This article examines the innovation of self-assembling enveloped virus-mimicking particles (EVMPs) for efficient, safe, and programmable mRNA delivery to extrahepatic tissues. The reference study demonstrates that rationally engineered EVMPs can overcome hepatic tropism and immunogenicity limitations, enabling robust transfection in organs such as the lung and spleen, with significant implications for mRNA therapeutics beyond the liver.

• Lactate-GPR81-Rac1 Axis Enables Insulin-Independent Glucose

  2026-06-09

  This study identifies L-lactate as a key regulator of glucose uptake independent of insulin, acting via GPR81 and downstream activation of Rac1 signaling. The findings reveal a metabolic control axis with implications for diabetes research, highlighting new strategies to improve glucose homeostasis beyond classical insulin signaling.

• Cy5 NHS ester(Et): Technical Guidance for Protein Labeling

  2026-06-08

  Cy5 NHS ester(Et) is a water-soluble fluorescent dye for labeling primary amines in proteins, peptides, and related biomolecules, making it valuable for immunofluorescence staining, flow cytometry, and fluorescence microscopy. It should not be used with ethanol-based protocols or for long-term storage of dye solutions; immediate use after dissolution is recommended for optimal labeling efficiency.

• S Tag Peptide (A6007): Technical Guidance for Fusion Tag Wor

  2026-06-08

  S Tag Peptide (A6007) addresses challenges in recombinant protein detection and purification by enhancing solubility and enabling robust antibody-based workflows. It is best suited for molecular biology protocols where tag structure independence is not required or where ethanol-based solvents are avoided.

• Gefitinib (ZD1839): Applied Workflows in Assembloid Cancer M

  2026-06-07

  Gefitinib (ZD1839) empowers researchers to probe EGFR signaling and drug resistance within complex tumor-stroma assembloids, enabling physiologically relevant, personalized insights. This article details optimized experimental workflows, troubleshooting strategies, and practical integration of Gefitinib into advanced preclinical models.

16416 records 1/1095 page Next 12345 下5页 Last page